Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gastrin is a peptide hormone that primarily stimulates the secretion of gastric acid by the parietal cells of the stomach and aids in gastric motility. In a therapeutic context, gastrin analogues (such as G1) are being investigated for their potential to induce pancreatic beta-cell neogenesis and regeneration, particularly when administered in combination with epidermal growth factor (EGF) analogues like E1. This regenerative approach is aimed at restoring endogenous insulin production in patients with Type 1 Diabetes. Additionally, in certain clinical trial contexts, the term "gastrin" (or gastric membrane extract/gastromucin) refers to a substance used for its mucosal protective properties in the treatment of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, often in combination with probiotics like Mutaflor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gastrin.